MedTrace Logo

AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers

NCT03215381 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-02-26

No results posted yet for this study

Summary

This is an open-label, single centre exploratory study to analyse brain exposure of AZD1390 in healthy volunteer males.

Conditions

  • Healthy Volunteer Male Subjects

Interventions

DRUG

[11C]AZD1390

\[11C\]AZD1390

Sponsors & Collaborators

  • Karolinska Institutet, Quintiles IMS

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-10
Primary Completion
2018-02-19
Completion
2018-02-19

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03215381 on ClinicalTrials.gov